Mabwell (688062.SH), a biopharmaceutical company, announced on Friday that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its self-developed novel Nectin-4-targeting ADC (R&D Code: 9MW2821) intended to treat locally advanced or metastatic Nectin-4 positive triple negative breast cancer (TNBC).
This move is aimed at accelerating the development and review of pharmaceuticals used to treat critical conditions, therefore lowering the time required to bring these drugs to market.
The product has received multiple regulatory designations from the FDA within the last six months. Previously, the product received FTD for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) and recurrent or metastatic cervical cancer (CC) progressed on or subsequent to prior treatment with a platinum-based chemotherapy regimen, and also received Orphan Drug Designation (ODD) for the treatment of esophageal cancer (EC).
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment